
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Polycystic ovary syndrome causes
Introduction
Overview
Overview
The underlying defect in patients with polycystic ovary syndrome (PCOS) remains unknown, but a hormonal imbalance between LH/FSH and estrogen is mainly responsible for the development of polycystic ovary syndrome. Most studies suggest that more than one factor could play a role in developing Polycystic ovary syndrome (PCOS).
Causes
Causes
The underlying defect in patients with polycystic ovary syndrome (PCOS) remains unknown and is thought to be multifactorial, but abnormal gonadotropin dynamics are mainly responsible for the development of polycystic ovary syndrome. It is suggested that more than one factor could play a role in developing PCOS.[1][2][3]
- Increased gonadotropin-releasing hormone secretion in the pituitary gland results in increased secretion of serum luteinizing hormone (LH) and an elevated LH/follicle-stimulating hormone (FSH) ratio.
- Hypersecretion of LH results in increased ovarian androgen production, leading to arrest of follicular development with follicular atresia which may result in multiple cysts formation in the ovaries, and anovulatory cycles.
- Genes are thought to be another factor. The genetic component appears to be inherited in an autosomal dominant fashion with high genetic penetrance but variable expressivity in females
- The phenotype appears to manifest itself at least partially via heightened androgen levels secreted by ovarian follicle theca cells from women with the allele.
- The exact gene affected has not yet been identified.
- In rare instances, single-gene mutations can give rise to the phenotype of the syndrome.
References
References
- ↑ Strauss JF (2003). “Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome”. Ann. N. Y. Acad. Sci. 997: 42–8. PMID 14644808.
- ↑ Bednarska S, Siejka A (2017). “The pathogenesis and treatment of polycystic ovary syndrome: What’s new?”. Adv Clin Exp Med. 26 (2): 359–367. PMID 28791858.
- ↑ Kassi E, Diamanti-Kandarakis E (2008). “The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome”. J. Endocrinol. Invest. 31 (12): 1124–31. doi:10.1007/BF03345663. PMID 19246981.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
